.png)
TL;DRThe fixed reference price (Festbetrag) is the maximum amount the German statutory health insurance (gesetzliche Krankenversicherung, GKV) pays for a medicine. The legal basis is §35 SGB V. The distinction that matters: a Festbetrag is a reimbursement ceiling, not a price cap. A manufacturer remains free to set any price it wants. What the Festbetrag decides is how much of that price the sickness fund carries.
§31 Abs. 2 SGB V states it directly: for a medicine with a Festbetrag, the fund bears the cost bis zur Höhe dieses Betrages (up to the level of that amount). Everything above the ceiling is paid by the insured person. That is why the Festbetrag acts as a price magnet rather than a prohibition. A manufacturer pricing above it has to justify a surcharge the patient feels at the counter, so most prices converge downward onto the ceiling instead.
Responsibility is split between two bodies, and confusing them is the most common error in this area. The process runs in two stages.
Put simply: the G-BA decides which products compete, the GKV-Spitzenverband decides what that competition is worth. Festbeträge must be reviewed at least once a year and adjusted to changed market conditions at suitable intervals.
§35 Abs. 1 Satz 2 SGB V defines three levels, known as Gruppenstufen. The level determines how much clinical judgement goes into a group and how contested it tends to be.
| Stufe | Legal wording (§35 Abs. 1 Satz 2) | What it means | Example |
|---|---|---|---|
| Stufe 1 | Arzneimittel mit denselben Wirkstoffen | Identical active ingredient. The classic generics group. Differing bioavailability must be taken into account where it matters therapeutically. | All ibuprofen 400 mg products |
| Stufe 2 | pharmakologisch-therapeutisch vergleichbaren Wirkstoffen, insbesondere mit chemisch verwandten Stoffen | Different active ingredients from the same pharmacological class. This is the level at which patent-protected products can be captured. | Sartans, proton pump inhibitors |
| Stufe 3 | therapeutisch vergleichbarer Wirkung, insbesondere Arzneimittelkombinationen | Different mechanisms, comparable therapeutic effect. Explicitly includes combination products. | Combination products with comparable effect |
Groups at Stufe 2 and Stufe 3 carry an extra guardrail: they must not restrict treatment options, and medically necessary prescribing alternatives must remain available. Reserve antibiotics can be excluded from grouping, and age-appropriate paediatric forms and strengths stay out under §35 Abs. 1a SGB V.
The core rule sits in §35 Abs. 5 Satz 4 SGB V. The Festbetrag soll den höchsten Abgabepreis des unteren Drittels des Intervalls zwischen dem niedrigsten und dem höchsten Preis einer Standardpackung nicht übersteigen. In other words: take the price range for a standard pack across the group, cut off the lower third, and the Festbetrag should not exceed the highest actual price found inside that lower third. No public explainer works this through, so here is an illustrative example.
Those figures are constructed to show the mechanics; they are not from a real group. A second statutory test then has to hold. At least one fifth of all prescriptions and at least one fifth of all packages in the group must be available at the Festbetrag, and the sum of the two percentages for what is not available at it must not exceed the value of 160. High-priced packs accounting for under one percent of prescribed packages are left out of that calculation. This test is why a Festbetrag cannot simply be pushed toward the theoretical minimum: enough real supply has to sit at the ceiling.
This distinction decides what a patient actually pays, and it is routinely blurred. They are two separate payments that can fall due at the same time on the same pack.
| Zuzahlung (statutory copayment) | Aufzahlung (excess payment) | |
|---|---|---|
| Legal basis | §31 Abs. 3 SGB V in conjunction with §61 Satz 1 | §31 Abs. 2 SGB V, the fund pays only up to the Festbetrag |
| Trigger | Applies to essentially every medicine prescribed at GKV expense | Applies only when the price exceeds the Festbetrag |
| Amount | 10 percent of the cost, minimum 5 euro, maximum 10 euro, never more than the cost of the product | The full difference between the actual price and the Festbetrag, uncapped |
| Counts toward the Belastungsgrenze | Yes | No |
| Avoidable | Only through an exemption | Yes, by dispensing a product priced at or below the Festbetrag |
Two consequences follow. First, an Aufzahlung is uncapped and does not count toward the annual hardship ceiling, which makes it the more painful of the two for a chronically ill patient. Second, there is a release valve at the other end: under §31 Abs. 3 Satz 4 SGB V the GKV-Spitzenverband may exempt a medicine from the Zuzahlung entirely where the manufacturer price excluding VAT is at least 20 percent below the applicable Festbetrag. That threshold is often quoted as 30 percent, which does not match the current statute.
There is also a bridge to the rebate world. Under §31 Abs. 2 SGB V, if a fund has concluded an agreement under §130a Abs. 8 SGB V with a company offering a Festbetrag medicine, the fund bears the pharmacy retail price instead, and the Aufzahlung disappears for the insured person. Such an agreement is only permissible if it offsets the excess over the Festbetrag.
Yes, with one carve-out. §35 Abs. 1 Satz 6 SGB V exempts from Stufe 2 and Stufe 3 groups only those Arzneimittel mit patentgeschützten Wirkstoffen, deren Wirkungsweise neuartig ist oder die eine therapeutische Verbesserung, auch wegen geringerer Nebenwirkungen, bedeuten. A substance counts as neuartig for as long as the first substance marketed in its group remains patent-protected. Everything patent-protected but therapeutically unremarkable, the classic analogue preparation, can be grouped.
This became operational with the GKV-Modernisierungsgesetz (GMG), in force on 1 January 2004. The G-BA resolved the first Festbetrag groups including patent-protected products on 15 June 2004, covering proton pump inhibitors, sartans and triptans.
The link to AMNOG runs through §35a Abs. 4 SGB V. Where the benefit assessment establishes no therapeutic improvement for a medicine, it is to be assigned in the resolution under §35a Abs. 3 to the Festbetrag group of pharmacologically-therapeutically comparable medicines, that is, a Stufe 2 group. A separate legal challenge against that inclusion is inadmissible under §35a Abs. 8 SGB V.
| Date | Event |
|---|---|
| 1 January 1989 | SGB V enters into force as Article 1 of the Gesundheits-Reformgesetz (GRG) of 20 December 1988. §35 establishes Festbeträge for medicines. |
| 1 January 2004 | The GKV-Modernisierungsgesetz (GMG) enters into force. The G-BA may include patent-protected analogue preparations irrespective of their remaining patent term. |
| 16 March 2004 | The ECJ rules in joined cases C-264/01, C-306/01, C-354/01 and C-355/01 (AOK-Bundesverband and others) that associations of sickness funds are not undertakings within the meaning of Article 81 EC when they set Festbeträge. EU competition law does not reach the act of setting them. |
| 15 June 2004 | The G-BA resolves the first Festbetrag groups including patent-protected medicines: proton pump inhibitors, sartans and triptans. |
The fixed reference price reaches the platform through the licensed ABDA article master data. It is not a separate lookup: the FB value sits in the header price cascade alongside APU, EK, VK and RAB, so the gap between retail price and ceiling is visible without opening a tab.
One honest limitation: the FB field tells you which amount applies, not why the group was cut the way it was. The reasoning behind a grouping lives in the G-BA decision documents, and the legally authoritative overview of all Festbetrag medicines on the market is the one the GKV-Spitzenverband publishes via the BfArM under §35 Abs. 8 SGB V. If you need to argue about a grouping rather than apply it, that is where you go.
